{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T01:37:16Z","timestamp":1767922636819,"version":"3.49.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.2515\/therapie\/2011010","type":"journal-article","created":{"date-parts":[[2011,6,3]],"date-time":"2011-06-03T15:11:49Z","timestamp":1307113909000},"page":"115-122","source":"Crossref","is-referenced-by-count":4,"title":["Niveau de preuve du suivi th\u00e9rapeutique pharmacologique du posaconazole"],"prefix":"10.1016","volume":"66","author":[{"given":"Sandrine","family":"Lefeuvre","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed-Larbi","family":"Jelassi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amine","family":"Benlmouden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maud","family":"Berge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Le Guellec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliane M.","family":"Billaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2011010_bb0005","first-page":"29","article-title":"M\u00e9thodologie pour l\u2019\u00e9valuation du niveau de preuve du suivi th\u00e9rapeutique pharmacologique","volume":"23","author":"Le Guellec","year":"2009","journal-title":"La Lettre du Pharmacologue"},{"key":"10.2515\/therapie\/2011010_bb0010","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1128\/AAC.00496-07","article-title":"In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European committee on antimicrobial susceptibility testing","volume":"51","author":"Lortholary","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011010_bb0015","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1086\/523576","article-title":"Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent","volume":"45","author":"Nagappan","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2011010_bb0020","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2146\/ajhp070532","article-title":"Posaconazole: a new oral antifungal agent with an expanded spectrum of activity","volume":"66","author":"Morris","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"10.2515\/therapie\/2011010_bb0025","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1128\/AAC.47.9.2788-2795.2003","article-title":"Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults","volume":"47","author":"Courtney","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011010_bb0030","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1128\/AAC.48.9.3543-3551.2004","article-title":"Disposition of posaconazole following single-dose oral administration in healthy subjects","volume":"48","author":"Krieter","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011010_bb0035","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.2165\/00003495-200565110-00007","article-title":"Posaconazole","volume":"65","author":"Keating","year":"2005","journal-title":"Drugs"},{"key":"10.2515\/therapie\/2011010_bb0040","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ejps.2004.01.005","article-title":"Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study","volume":"21","author":"Wexler","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"10.2515\/therapie\/2011010_bb0045","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1128\/AAC.00472-06","article-title":"Effects of age, gender, and race\/ethnicity on the pharmacokinetics of posaconazole in healthy volunteers","volume":"51","author":"Sansone-Parsons","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011010_bb0050","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2125.2003.01977.x","article-title":"Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults","volume":"57","author":"Courtney","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011010_bb0055","doi-asserted-by":"crossref","first-page":"211","DOI":"10.2165\/00003088-200544020-00006","article-title":"Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations","volume":"44","author":"Ezzet","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.2515\/therapie\/2011010_bb0060","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1086\/504328","article-title":"Safety of long-term oral posaconazole use in the treatment of refractory invasive fungal infections","volume":"42","author":"Raad","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2011010_bb0065","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1056\/NEJMoa061094","article-title":"Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia","volume":"356","author":"Cornely","year":"2007","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie\/2011010_bb0070","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa061098","article-title":"Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease","volume":"356","author":"Ullmann","year":"2007","journal-title":"N Engl J Med"},{"key":"10.2515\/therapie\/2011010_bb0075","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.48.1.137-142.2004","article-title":"Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis","volume":"48","author":"Andes","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011010_bb0080","series-title":"Noxafilr\u00ae posaconazole","author":"Vidal","year":"2010"},{"key":"10.2515\/therapie\/2011010_bb0085","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1086\/508774","article-title":"Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial","volume":"44","author":"Walsh","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2011010_bb0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1128\/AAC.00705-08","article-title":"Antifungal therapeutic drugmonitoring: established and emerging indications","volume":"53","author":"Andes","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011010_bb0095","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/QCO.0b013e3283184611","article-title":"Therapeutic drug monitoring for triazoles","volume":"21","author":"Hope","year":"2008","journal-title":"Curr Opin Infect Dis"},{"key":"10.2515\/therapie\/2011010_bb0100","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1592\/phco.27.12.1627","article-title":"Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease","volume":"27","author":"Krishna","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.2515\/therapie\/2011010_bb0105","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1592\/phco.28.10.1223","article-title":"Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome","volume":"28","author":"Krishna","year":"2008","journal-title":"Pharmacotherapy"},{"key":"10.2515\/therapie\/2011010_bb0110","series-title":"Posaconazole. FDA briefing document","author":"FDA","year":"2009"},{"key":"10.2515\/therapie\/2011010_bb0115","doi-asserted-by":"crossref","first-page":"5224","DOI":"10.1128\/AAC.00939-09","article-title":"Therapeutic drug monitoring of posaconazole: a monocentric study with 54 adults","volume":"53","author":"Lebeaux","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011010_bb0120","series-title":"P1751. European Congress of Clinical Microbiology and Infectious Diseases","author":"Berge","year":"2009"},{"key":"10.2515\/therapie\/2011010_bb0125","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1128\/AAC.50.2.658-666.2006","article-title":"Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection","volume":"50","author":"Ullmann","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011010_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1185\/03007990903364657","article-title":"Pharmacokinetics of a single dose of the antifungal posaconazole as oral suspension in subjects with hepatic impairment","volume":"26","author":"Moton","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.2515\/therapie\/2011010_bb0135","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1086\/650740","article-title":"Rifampin and posaconazole coadministration leads to decreased serum posaconazole concentrations","volume":"50","author":"Hohmann","year":"2010","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2011010_bb0140","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1185\/030079906X167507","article-title":"Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men","volume":"23","author":"Krishna","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.2515\/therapie\/2011010_bb0145","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/QAI.0b013e3181acb51b","article-title":"Effects of oral posaconazole on the pharmacokinetics of atazanavir alone and with ritonavir or with efavirenz in healthy adult volunteers","volume":"51","author":"Krishna","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.2515\/therapie\/2011010_bb0150","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1185\/030079907X187937","article-title":"Drug interaction assessment following concomitant administration of posaconazole and phenytoin in healthy men","volume":"23","author":"Krishna","year":"2007","journal-title":"Curr Med Res Opin"},{"key":"10.2515\/therapie\/2011010_bb0155","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1128\/AAC.48.3.804-808.2004","article-title":"Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men","volume":"48","author":"Courtney","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.2515\/therapie\/2011010_bb0160","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1086\/597110","article-title":"Omeprazole significantly reduces posaconazole serum trough level","volume":"48","author":"Alffenaar","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2011010_bb0165","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1086\/598327","article-title":"Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents","volume":"48","author":"Bruggemann","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2011010_bb0170","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1086\/504492","article-title":"Pharmacology of systemic antifungal agents","volume":"43","author":"Dodds-Ashley","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.2515\/therapie\/2011010_bb0175","series-title":"P1667. European Congress of Clinical Microbiology and Infectious Diseases","author":"Baloul","year":"2009"},{"key":"10.2515\/therapie\/2011010_bb0180","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1399-3062.2009.00384.x","article-title":"Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients","volume":"11","author":"Berge","year":"2009","journal-title":"Transpl Infect Dis"},{"key":"10.2515\/therapie\/2011010_bb0185","doi-asserted-by":"crossref","first-page":"481","DOI":"10.2165\/00044011-200929070-00006","article-title":"Management of metabolic cytochrome P450 3A4 drug-drug interaction between everolimus and azole antifungals in a renal transplant patient","volume":"29","author":"Billaud","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.2515\/therapie\/2011010_bb0190","first-page":"271","article-title":"Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients","volume":"46","author":"Billaud","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.2515\/therapie\/2011010_bb0195","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1097\/FTD.0b013e31819de6fd","article-title":"Safe management of tacrolimus together with posaconazole in lung transplant patients with cystic fibrosis","volume":"31","author":"Berge","year":"2009","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.2515\/therapie\/2011010_bb0200","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1185\/03007990802644209","article-title":"Effects of oral posaconazole on the pharmacokinetics of sirolimus","volume":"25","author":"Moton","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.2515\/therapie\/2011010_bb0205","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1592\/phco.27.6.825","article-title":"Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus","volume":"27","author":"Sansone-Parsons","year":"2007","journal-title":"Pharmacotherapy"},{"key":"10.2515\/therapie\/2011010_bb0210","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/bdd.524","article-title":"Everolimus drug interactions: application of a classification system for clinical decision making","volume":"27","author":"Kovarik","year":"2006","journal-title":"Biopharm Drug Dispos"},{"key":"10.2515\/therapie\/2011010_bb0215","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jchromb.2009.11.017","article-title":"Method for therapeutic drug monitoring of azole antifungal drugs in human serum using LC\/MS\/MS","volume":"878","author":"Alffenaar","year":"2010","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.2515\/therapie\/2011010_bb0220","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/j.jpba.2009.06.030","article-title":"Simultaneous determination of five systemic azoles in plasma by high-performance liquid chromatography with ultraviolet detection","volume":"50","author":"Gordien","year":"2009","journal-title":"J Pharm Biomed Anal"},{"key":"10.2515\/therapie\/2011010_bb0225","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1128\/AAC.00663-08","article-title":"Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects","volume":"53","author":"Conte","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"10.2515\/therapie\/2011010_bb0230","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1128\/AAC.01407-09","article-title":"Intracellular concentrations of posaconazole in different compartments of the peripheral blood","volume":"54","author":"Farowski","year":"2010","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307454?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716307454?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T07:42:45Z","timestamp":1554277365000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716307454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0040595716307454"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2011010","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]}}}